title: A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
abstract: OBJECTIVE
  To compare 1-month and 3-month depot formulations of leuprolide acetate (DL), a gonadotropin-releasing hormone analog, in the treatment of central precocious puberty (CPP).
  
  
  METHODS
  Subjects with CPP naïve to therapy were randomized to 7.5 mg of 1-month DL, 11.25 mg of 3-month DL, or 22.5 mg of 3-month DL. Stimulated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and estradiol levels, growth velocity, and bone age progression were examined in a 2-year period.
  
  
  RESULTS
  Forty-nine female and 5 male subjects with CPP were randomized. Mean stimulated LH and FSH levels during treatment were higher in the low-dose 11.25-mg 3-month DL group, and more LH levels >4 IU/L were observed, in comparison with the other two dose groups. Mean LH and FSH levels in the 22.5-mg 3-month group were not different from the monthly DL. No differences in estradiol levels, growth velocity, or bone age progression were observed in dosing groups.
  
  
  CONCLUSIONS
  All DL doses resulted in prompt and effective suppression of puberty, but higher LH and FSH levels were seen with the 11.25-mg 3-month DL dose. Multi-monthly DL is effective in treating CPP, but higher dosing may be required in some circumstances.
authors.affiliation: Drexel University College of Medicine, Philadelphia, PA, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Fuld
authors.forename: Carolyn
authors.initials: C
authors.lastname: Chi
authors.forename: E Kirk
authors.initials: EK
authors.lastname: Neely
mesh_terms: D002648:Child; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D016729:Leuprolide